No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HRTX240621C1000
- 2.78
- +0.38+15.83%
15min DelayClose May 31 16:00 ET
2.78High2.78Low
2.78Open2.40Pre Close10 Volume395 Open Interest1.00Strike Price2.78KTurnover0.00%IV0.00%PremiumJun 21, 2024Expiry Date2.70Intrinsic Value100Multiplier18DDays to Expiry0.08Time Value100Contract SizeAmericanOptions Type--Delta--Gamma1.37Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody
Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Heron Therapeutics, Inc. (NASDAQ:HRTX) shares have had a really impressive month, gaining 31% after a shaky period beforehand.
J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
Pleasing Signs As A Number Of Insiders Buy Heron Therapeutics Stock
Express News | Heron Therapeutics Announces Prior Approval Supplement Submission To FDA For ZYNRELEF VAN
Comments
$Heron Therapeutics(HRTX.US$ Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for Zynrelef® Vial Access Needle ("Van")
1
1
$Heron Therapeutics(HRTX.US$
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics announced the submission of a Prior Approval Supplement (PAS) to the FDA for the ZYNRELEF Vial Access Needle (VAN). The VAN aims to replace the current vented vial spike (VVS) in ZYNRELEF kits, reducing preparation time significantly from up to 3 minutes to 20-45 seconds. The VAN's user-friendly design is expected to simplify a...
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
Heron Therapeutics announced the submission of a Prior Approval Supplement (PAS) to the FDA for the ZYNRELEF Vial Access Needle (VAN). The VAN aims to replace the current vented vial spike (VVS) in ZYNRELEF kits, reducing preparation time significantly from up to 3 minutes to 20-45 seconds. The VAN's user-friendly design is expected to simplify a...
1
Heron Therapeutics' stock price surge may be positive, but the company's core business performance will decide the sustainability of this turnaround. Lack of profitability and minimal revenue growth could discourage potential investors.
1
Heron Therapeutics' projected breakeven and profitability rely on optimistic growth estimates. The company's negative equity, possibly due to accounting methods, raises concerns.
📌Last week’s PDUFAs:
$Heron Therapeutics(HRTX.US$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US$ & $Regeneron Pharmaceuticals(REGN.US$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
$Heron Therapeutics(HRTX.US$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US$ & $Regeneron Pharmaceuticals(REGN.US$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
12
1
Read more
TrytosaveabitOP : Before EOY ((((. Heron Anticipates FDA Action on Zynrelef Within 4-6 Months ))))